Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 11/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1379668 | 0.90 | ALDH1A1 (0.43) | CYP1A2RAB9AL3MBTL1LMNAPOLB | |
| SCHEMBL11861074 | 0.88 | CYP1A2 (0.53) | CYP1A2RAB9AL3MBTL1LMNAPOLB | |
| SCHEMBL7509641 | 0.87 | ALDH1A1 (0.45) | CYP1A2L3MBTL1LMNAALDH1A1PDE4D | |
| SCHEMBL1855324 | 0.84 | CYP1A2 (0.53) | CYP1A2RAB9AL3MBTL1LMNAPOLB | |
| SCHEMBL10084759 | 0.84 | CYP1A2 (0.50) | CYP1A2RAB9AL3MBTL1LMNAPOLB | |
| SCHEMBL6052421 | 0.83 | TSHR (0.48) | CYP1A2LMNATSHRALDH1A1 | |
| SCHEMBL1127701 | 0.83 | PAOX (0.51) | CYP1A2RAB9AL3MBTL1LMNAPOLB | |
| SCHEMBL856060 | 0.83 | CYP1A2 (0.56) | CYP1A2RAB9AL3MBTL1LMNAPOLB | |
| SCHEMBL1863035 | 0.83 | CYP1A2 (0.56) | CYP1A2RAB9AL3MBTL1LMNAPOLB | |
| SCHEMBL7515394 | 0.81 | DGKA (0.49) | L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112594-B2 | Fused bicyclic amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-09-26 | — | — | US | disclosed |
| EP-1176140-B1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| US-20030203909-A1 | Fused bicyclic amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-10-30 | — | — | US | disclosed |
| EP-1310488-A1 | FUSED BICYCLIC AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1176140-A1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203909-A1 | Fused bicyclic amide compounds and medicinal use thereof | BET1, NFATC1, ARG1 | CYP1A2 1060/4885RAB9A 3542/4885L3MBTL1 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.